Alterity Therapeutics Ltd 6-K, filed Jan 7, 2026
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on January 7, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 07, 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
| 99.1 | Change of Director's Interest Notice - D Stamler |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | ||
| By: | /s/ Julian Babarczy | |
| Julian Babarczy | ||
| Chairman | ||
Date: January 07, 2026
2
Exhibit 99.1
| Appendix 3Y |
| Change of Director’s Interest Notice |
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Alterity Therapeutics Limited |
| ABN | 37 080 699 065 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of director | David Stamler |
| Date of last notice | 21 November 2025 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest | HSBC CUSTODY NOMINEES (AUSTRALIA) |
| (including registered holder) | LIMITED - 133,333 - AMERICAN DEPOSITARY SHARES |
| (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) | |
| Date of change | (1) N/A |
| (2) N/A | |
| (3) N/A | |
| (4) N/A | |
| (5) 06 January 2026 | |
| (6) N/A | |
| (7) N/A | |
| No. of securities held prior to change | (1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT |
| (2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT | |
| (3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT | |
| (4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT | |
| (5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT | |
| (6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT | |
| (7) 133,333 - AMERICAN DEPOSITARY SHARES | |
| (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
| Appendix 3Y |
| Change of Director’s Interest Notice |
| Class |
(1) FULLY PAID ORDINARY SHARES (2) LISTED OPT EXP 31/08/2026 @ $0.01 (3) LISTED OPT EXP 26/02/2027 @ $0.028 (4) UNLISTED OPT EXP 21/03/2029 @ US$0.0030 (5) UNLISTED OPT EXP 06/01/2026 @ $0.0320 (6) UNLISTED OPT EXP 08/08/2030 @ US$0.0086 (7) AMERICAN DEPOSITARY SHARES |
| Number acquired |
(1) NIL (2) NIL (3) NIL (4) NIL (5) NIL (6) NIL (7) NIL |
| Number disposed |
(1) NIL (2) NIL (3) NIL (4) NIL (5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 (6) NIL (7) NIL |
| Value/Consideration |
(1) N/A (2) N/A (3) N/A (4) N/A (5) NIL (6) N/A (7) N/A |
| No. of securities held after change |
(1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT (2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT (3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT (4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT (5) NIL - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT (6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT (7) 133,333 - AMERICAN DEPOSITARY SHARES (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT |
| Nature of change |
(1) N/A (2) N/A (3) N/A (4) N/A (5) Options expired (6) N/A (7) N/A |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
| Appendix 3Y |
| Change of Director’s Interest Notice |
Part 2 - Change of director’s relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration | N/A |
| Interest after change | N/A |
Part 3 - +Closed period
|
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3